Edition:
India

Cellmid Ltd (CDY.AX)

CDY.AX on Australia Stock Exchange

0.22AUD
14 Oct 2019
Change (% chg)

$0.00 (+0.00%)
Prev Close
$0.22
Open
$0.22
Day's High
$0.23
Day's Low
$0.22
Volume
141,431
Avg. Vol
70,279
52-wk High
$0.38
52-wk Low
$0.17

Latest Key Developments (Source: Significant Developments)

Cellmid Signs New Distribution Agreement For Évolis And Opens In Europe
Tuesday, 1 Oct 2019 

Oct 1 (Reuters) - Cellmid Ltd ::CELLMID - CELLMID HAS ENTERED INTO A SUPPLY AGREEMENT FOR ITS ÉVOLIS PROFESSIONAL ANTI-AGING HAIR CARE AND HAIR LOSS PRODUCTS WITH DOUGLAS GMBH.CELLMID -SIGNED EXCLUSIVE DISTRIBUTION AGREEMENT WITH AEON INTERNATIONAL FOR ÉVOLIS PROFESSIONAL TO BE SOLD IN CHINESE CROSS-BORDER E-COMMERCE MARKET.  Full Article

Cellmid Receives Notification Of Intention To Grant "Improved Midkine Antibody" Patent
Thursday, 22 Aug 2019 

Aug 22 (Reuters) - Cellmid Ltd ::CELLMID - GOT NOTIFICATION OF INTENTION TO GRANT FROM EUROPEAN PATENT OFFICE FOR "IMPROVED MIDKINE ANTIBODY" PATENT IN KEY EUROPEAN TERRITORIES.  Full Article

Cellmid Generated $2.45 Million In Sales In Q4 FY2019, Up 83%
Friday, 26 Jul 2019 

July 26 (Reuters) - Cellmid Ltd ::GENERATED $2.45 MILLION IN SALES IN Q4 FY2019, UP 83%.  Full Article

Cellmid Sees Q4 Sales At $2.45 Million
Thursday, 4 Jul 2019 

July 4 (Reuters) - Cellmid Ltd ::SALES FOR 4Q FY2019 ARE EXPECTED TO REACH $2.45 MILLION.  Full Article

Cellmid On Track To Achieve Record Revenue In Fy2019
Tuesday, 28 May 2019 

May 28 (Reuters) - Cellmid Ltd ::Q3 SALES UP 25% ON PREVIOUS CORRESPONDING QUARTER.ON TRACK TO ACHIEVE RECORD REVENUE IN FY2019.  Full Article

Cellmid Posts H1 Revenue Of $3.6 Mln
Thursday, 21 Feb 2019 

Feb 21 (Reuters) - Cellmid Ltd ::H1 REVENUE OF $3.6 MILLION WAS UP 12%.HY NET LOSS AFTER TAX FOR THE PERIOD ATTRIBUTABLE TO MEMBERS $3.5 MILLION VERSUS $1.1 MILLION.  Full Article

Cellmid Announces New Patents for Midkine Antibodies in USA and Europe
Wednesday, 7 Nov 2018 

Nov 7 (Reuters) - Cellmid Ltd ::EUROPEAN PATENT OFFICE ISSUES INTENTION TO GRANT FOR MIDKINE N-DOMAIN ANTIBODY PATENT.PATENT COVERING LYRAMID'S ANTIBODY RECOGNIZING N-DOMAIN OF MIDKINE GRANTED IN USA.HAS RECENTLY FILED TWO NEW PROVISIONAL PATENT APPLICATIONS FOR LYRAMID'S N-DOMAIN ANTIBODIES.  Full Article

Cellmid Enter Agreement With Labo International S.R.L
Wednesday, 4 Apr 2018 

April 4 (Reuters) - Cellmid Ltd ::ENTERED INTO AN AGREEMENT WITH LABO INTERNATIONAL S.R.L TO UNDERTAKE EXCLUSIVE DISTRIBUTION OF FILLERINA.  Full Article

Cellmid Says HY ‍Net Loss After Tax $1.1 Mln
Thursday, 22 Feb 2018 

Feb 22 (Reuters) - Cellmid Ltd ::HY ‍NET LOSS AFTER TAX $1.1 MILLION.  Full Article

Cellmid Ltd To Issue 2.7 Million Shares To Investor
Friday, 15 Dec 2017 

Dec 15 (Reuters) - Cellmid Ltd ::UNDER PLACEMENT CELLMID WILL ISSUE 2.7 MILLION SHARES AT 38 CENTS EACH TO INVESTOR REPRESENTING $1.0 MILLION.  Full Article